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The gene encoding the transcription factor C/EBPα is mutated in 10–15% of
acute myeloid leukemia (AML) patients. N-terminal CEBPA  mutations cause
ablation of  full-length C/EBPα  without  affecting the expression of  a  shorter
oncogenic  isoform,  termed  p30.  The  mechanistic  basis  of  p30-induced
leukemogenesis  is  incompletely  understood.  Here,  we  demonstrate  that  the
MLL1  histone-methyltransferase  complex  represents  a  critical  actionable
vulnerability  in  CEBPA-mutated  AML.  Oncogenic  C/EBPα  p30  and  MLL1
show  global  co-localization  on  chromatin  and  p30  exhibits  robust  physical
interaction with the MLL1 complex. CRISPR/Cas9-mediated mutagenesis  of
MLL1  results  in  proliferation  arrest  and  myeloid  differentiation  in  C/EBPα
p30-expressing cells.  In line,  CEBPA-mutated hematopoietic  progenitor  cells
are  hypersensitive  to  pharmacological  targeting  of  the  MLL1  complex.
Inhibitor  treatment  impairs  proliferation and restores  myeloid  differentiation
potential in mouse and human AML cells with CEBPA mutations. Finally, we
identify the transcription factor GATA2 as a direct critical target of the p30-
MLL1 interaction. Altogether, we show that C/EBPα  p30 requires the MLL1
complex to regulate oncogenic gene expression and that CEBPA-mutated AML
is  hypersensitive  to  perturbation  of  the  MLL1  complex.  These  findings
identify  the  MLL1  complex  as  a  potential  therapeutic  target  in  AML  with
CEBPA mutations.
Aberrant myeloid homeostasis in Acute myeloid leukemia (AML) leads to an
increase in myeloid progenitor cells at the expense of mature blood cells [1]. Ten
to fifteen percentage of AML patients harbor mutations in the CEBPA gene [2, 3,
4], which encodes the transcription factor (TF) CCAAT/enhancer binding protein
alpha (C/EBPα). C/EBPα In the PDF document, this word is seperated over the line
7
e.Proofing http://eproofing.springer.com/journals_v2/printpage.php?token=D-yxEj...
3 von 27 14.01.2019, 14:29
break. Please keep as one word  controls self-renewal properties of hematopoietic
stem and progenitor cells (HSPCs) as well as critical steps of myeloid
differentiation [5, 6, 7]. Alternative usage of different translation initiation
codons results in the expression of full-length (42 kDa) and truncated (30 kDa)
isoforms of C/EBPα, termed p42 and p30, respectively [8].
AQ1
AQ2
AQ3
AQ4
AQ5
In AML, CEBPA mutations frequently occur in the N-terminal part of the gene
and introduce frameshifts that result in selective ablation of p42. Most AML
patients carry biallelic CEBPA mutations, combining an N-terminal frameshift
with a C-terminal in-frame mutation, which abolishes dimerization and DNA
binding [9, 10].
C/EBPα p30 is able to regulate transcriptional processes through recruitment of
chromatin-modifying complexes, such as histone methyltransferases [6, 11, 12].
For instance, p30 interacts with WDR5, a component of several protein
complexes involved in transcriptional control [13]. These assemblies include
SET/MLL complexes which positively regulate gene expression by catalyzing
tri-methylation of lysine 4 of histone H3 (H3K4me3) and are crucial for the
maintenance of HSPCs [14, 15, 16, 17]. Assembly of different members of the
histone-methyltransferase mixed-lineage leukemia family (MLL1-4, also referred
to as KMT2A-D) with their conserved binding partners WDR5, RBBP5, ASH2L,
and DPY30 is necessary for full enzymatic activity of SET/MLL complexes [18,
19, 20]. Other interaction partners such as Menin and Lens epithelium-derived
growth factor (LEDGF, PSIP1) mediate chromatin recruitment of SET/MLL
complexes [21, 22, 23]. We hypothesized that p30 and the MLL1 (KMT2A)
complex cooperate in the regulation of transcriptional programs that are critical
for leukemogenesis.
We used a combination of biochemical, genetic and pharmacological approaches
to investigate the role of the MLL1 complex in CEBPA-mutated AML. We show
that p30 interacts with the MLL1 complex to control gene expression. Genetic
and pharmacological targeting of the MLL1 complex caused proliferation arrest
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and induced myeloid differentiation in C/EBPα-mutated AML cells. These data
identify the transcriptional cooperation between C/EBPα p30 and MLL1 as an
actionable vulnerability in CEBPA-mutated AML.
An SpCas9-expressing subclone of Cebpa  cells was isolated after lentiviral
expression of lenti-Cas9-Blast (Addgene, Cambridge, MA, USA). SpCas9-
Cebpa  cells were transduced with sgRNA-containing LentiGuide-Puro-
IRES-GFP constructs (Supplemental Table S1) in biological duplicates, obtaining
transduction efficiencies of 20–40%. GFP levels were monitored by flow
cytometry over time. Data were normalized to values on day 0 (normalized
sgRNA = %GFP(dX)/%GFP(d0)) and a non-targeting control sgRNA (Ctrl,
(normalized Ctrl/normalized sgRNA) *100%).
Cebpa  cells were crosslinked with 11% formaldehyde (Thermo Fisher
Scientific, Waltham, MA, USA) alone ( C/EBPα In the PDF document, this word
is seperated over the line break. Please keep as one word ) or with 2 mM
disuccinimidyl glutarate (DSG, THP, Vienna, Austria) (MLL1). After quenching,
cells were lysed in SDS-containing buffer (Sigma-Aldrich, St. Louis, MO, USA)
and incubated with anti-MLL1 (Bethyl Laboratories, Montgomery, TX, USA,
A300-086A) and anti-C/EBPα (Santa Cruz, Dallas, Texas, USA, sc-9314)
antibodies overnight. After isolating antibody-bound material using protein
G-coupled magnetic beads (Dynabeads Protein G, Invitrogen, Camarillo, CA,
USA) and de-crosslinking, enrichment of genomic regions was measured by
qPCR (Supplemental Table S2).
Cells were seeded in 96-well plates and treated with MI-463 or MI-503 in
biological triplicates at indicated concentrations. Five days after treatment, cell
viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay
(Promega, Madison, WI, USA) on a VICTOR X3 luminometer (PerkinElmer,
Waltham, MA, USA).
p30/p30
p30/p30
p30/p30
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Prism 5.01 software (Graphpad, La Jolla, CA, USA) was used for statistical
analyses and data are shown as mean ± SD. Experiments were performed in
duplicates/triplicates and/or repeated at least three times. Two-tailed Student’s
t-tests were used for P value determination: *P < 0.05; **P < 0.01; ***P < 0.001,
and ****P < 0.0001.
Additional Materials and methods are described in Supplementary Methods.
To investigate whether p30 cooperates with the MLL1 complex in transcriptional
regulation we used a myeloid progenitor cell line derived from a mouse model of
CEBPA-N-terminal AML [24] (Cebpa ). Cebpa  cells appear as
cytokine-dependent leukemic blasts and co-express c-Kit and Mac-1
(Supplemental Figure S1A-C). These cells were dependent on the original p30
driver lesion for sustained proliferation in culture, as shRNA-mediated
knockdown of p30 resulted in immediate growth arrest (Supplemental
Figure S1D-E). Chromatin immunoprecipitation followed by sequencing (ChIP-
seq) using antibodies recognizing the C/EBPα C-terminus in Cebpa  cells
identified 24,538 genomic binding sites of the p30 protein, of which 19.9%
(4882 peaks) were localized within 3 kb of annotated transcription start sites
(TSS). ChIP-seq for MLL1 in Cebpa  cells identified 47,069 peaks of
which 24% (11,463 peaks) localized to promoter regions (Fig. 1a, Supplemental
Figure S1F). C/EBPα p30 binding showed a strong overlap with global MLL1
occupancy, as 73% of p30-bound promoters were also occupied by MLL1 (3549
of 4882 peaks, Fig. 1a). Consistent with ChIP-seq data, ChIP-qPCR confirmed
that p30 and MLL1 binding was detected at the Cyp51 promoter, but not at the
Kit promoter (Fig. 1b). Further, p30 co-precipitated with components of the
MLL1 core complex, including Wdr5, Rbbp5, and Ash2l, but also with the
canonical MLL1 binding partner Menin (Fig. 1c; Supplemental Figure S1G).
Fig. 1
Global  co-localization of  C/EBPα  p30 and MLL1 in Cebpa  cells.  a  Left,
heatmap showing p30 and MLL1 chromatin binding (< ± 3 kb of TSS). Right, Venn
diagram showing overlapping ChIP-seq peaks within ± 3 kb of TSS between p30
p30/p30 p30/p30
p30/p30
p30/p30
p30/p30
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(orange)  and MLL1 (blue).  b  qPCR analysis  (left),  and  ChIP-seq  tracks  (right)
showing  p30  and  MLL1  binding  in  promoters  of  indicated  genes.  Red  lines
indicate position of ChIP-qPCR products. c Western blot (WB) analysis of lysates
and  FLAG-purifications  from  extracts  of  HEK293  cells  expressing  indicated
constructs using indicated antibodies. Mw, molecular weight
Thus, these results indicate that p30 interacts with canonical MLL1 complexes in
Cebpa  cells.p30/p30
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The prominent genomic co-localization of p30 and MLL1 suggests a functional
role of MLL1 in CEBPA-N-terminal AML. We isolated and characterized an
SpCas9-expressing subclone from Cebpa  cells (Supplemental Figure S2A-
B) and transduced it with lentiviral vectors enabling sgRNA expression coupled
to a GFP reporter gene. This allows dynamic monitoring of competing growth
kinetics of sgRNA-expressing GFP-positive (GFP ) cells versus uninfected GFP-
negative (GFP ) cells (Fig. 2a). In contrast to a control sgRNA (Ctrl), targeting of
Rpa3, a known essential gene for DNA replication, resulted in fast negative
selection of GFP  cells (Fig. 2a). Similarly, CRISPR/Cas9-mediated mutagenesis
of p30 caused a strong proliferative disadvantage in this assay (Supplemental
Figure S2C-D). Cebpa targeting resulted in elevated levels of the maturation
surface markers Mac-1 and Gr-1 indicating increased signs of myeloid
differentiation (Supplemental Figure S2E).
Fig. 2
Cebpa  cells are dependent on a functional MLL1 protein. a Top, schematic
representation  of  the  CRISPR/Cas9-based  competition  assay.  Middle,  schematic
structure of the MLL1 protein. Positions of sgRNAs are indicated by dashed gray
lines and arrows. MBM, Menin-binding motif; CXXC, CXXC motif; PHD, plant
homeodomain finger; BD, bromodomain; WIN, WDR5-interacting domain; SET,
(enzymatic) Su(var)3-9, Enhancer-of-zeste and Trithorax domain. Bottom, heatmap
showing survival of GFP-positive (GFP ) sgRNA-expressing cells over time. Ctrl,
negative control; Rpa3, positive control. b Scatter plot representing percentages of
GFP  cells expressing indicated sgRNAs (day 28). Populations were divided into
three  groups  (Non-SET:  sgRNAs #1–10,  WIN:  sgRNAs #11–13,  SET:  sgRNAs
#14–20).  The  dashed  gray  line  indicates  the  percentage  of  GFP  cells  in
populations expressing a control sgRNA. c Flow cytometric analysis of Mac-1 and
Gr-1  after  Mll1  targeting  with  indicated  sgRNAs  (gated  on  GFP  cells).
Mac-1 Gr-1  levels are plotted for three groups (Ctrl, Non-SET: sgRNAs #1–10,
SET: sgRNAs #14–20)
p30/p30
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We investigated the functional role of MLL1 in N-terminal CEBPA-mutated
AML at domain resolution by CRISPR/Cas9-mediated mutagenesis of different
annotated domains in the Mll1 gene (Fig. 2a). In line with previous results [12],
mutation of the Wdr5-interacting domain (WIN) of MLL1 strongly impaired
proliferation of Cebpa In the PDF document, this word is seperated over the
line break. Please keep as one word  cells (Fig. 2a, b). Mutagenesis of MLL1
domains that are important for its integration into the MLL1 multiprotein
complex and for its chromatin recruitment, such as the Menin-binding-motif
p30/p30
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(MBM, sgRNAs #1–2), the CXXC motif (sgRNA #6), the plant homeodomain
(PHD, sgRNA #7), and the bromodomain (sgRNA #8), also caused strong anti-
proliferative effects (Fig. 2a, b). In contrast, mutational targeting of the
enzymatic SET domain did not affect proliferation (Fig. 2a, b), indicating that
the methyltransferase activity of MLL1 is not crucial for the maintenance of
CEBPA-N-terminal AML. While targeting the amino-terminus as well as
functional domains across the Mll1 gene resulted in increased signs of myeloid
differentiation, this effect was much weaker when the MLL1 SET domain was
mutated (Fig. 2c).
Taken together, multiple functional domains of the MLL1 protein are required for
proliferation of Cebpa  cells.
Given the genetic requirement for MLL1 in CEBPA-mutated AML, we reasoned
that pharmacological perturbation of the MLL1 complex could selectively target
p30-dependent cellular functions. MI-463 and MI-503 are potent small-molecule
inhibitors that disrupt the Menin-MLL interaction, thereby compromising the
integrity and function of the MLL1 complex [25, 26, 27]. Menin-MLL inhibitors
were shown to provide survival benefits in AML models with MLL-
rearrangements and NPM1 mutations [26, 28, 29].
Treatment of Cebpa  cells with MI-463 and MI-503 led to time- and dose-
dependent impairment of proliferation, induction of cell cycle arrest and
apoptosis (Fig. 3a–c; Supplemental Figure S3A-C). Cebpa  cells showed a
2.4–5.6-fold higher sensitivity toward Menin-MLL inhibition than leukemia cell
lines derived from different AML mouse models, including MLL-AF9/Nras ,
AML1-ETO9a/Nras /p53  or Myc/Nras /p53  (Fig. 3d, Supplemental
Figure S3D). Similarly, Cebpa  cells showed hypersensitivity toward
MI-463 and MI-503 when compared to a panel of human leukemia cell lines
representing different molecular aberrations (Fig. 3e, Supplemental Figure S3E).
Fig. 3
Pharmacological targeting of MLL1 function results in decreased self-renewal and
induction of apoptosis in Cebpa  cells. a Growth curves of Cebpa  cells
treated with indicated concentrations of MI-463 or DMSO. b Cell cycle analysis of
p30/p30
p30/p30
p30/p30
G12D
G12D −/− G12D −/−
p30/p30
p30/p30 p30/p30
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Cebpa  cells  at  indicated  time  points  after  MI-463  treatment.  c  Flow
cytometric analysis of apoptosis at indicated time points after MI-463 treatment. d,
e Representative dose response curves for MI-463 in Cebpa  cells (red) and
mouse (d) or human (e) leukemia cell lines
In AML with biallelic CEBPA mutations, p30 is the sole functional C/EBPα
protein, as C-terminal mutations give rise to dimerization- and DNA binding-
deficient proteins. A hematopoietic progenitor cell line derived from an AML
mouse model for biallelic CEBPA mutations [30] ( Cebpa In the PDF
p30/p30
p30/p30
p30/C-mut.
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document, this word is seperated over the line break. Please keep as one word ) was also
hypersensitive toward MI-463 and MI-503 treatment (Fig. 4a). Treatment of
Cebpa  cells resulted in time- and dose-dependent impairment of
proliferation and induction of apoptosis (Supplemental Figure S4A-B). Primary
fetal liver-derived hematopoietic progenitor cells from both Cebpa-mutated AML
mouse models were highly sensitive toward MI-463 and MI-503 treatment in
colony-formation assays, indicating that inhibitor hypersensitivity was not
acquired during the process of cell line establishment (Fig. 4b, Supplemental
Figure S4C). MLL1 complex perturbation caused loss of compact colony
formation and induced the formation of small, dispersed colonies reminiscent of
mature myeloid cell clusters (Supplemental Figure S4D).
Fig. 4
Cebpa  cells  and primary human AML cells  with CEBPA  mutations  are
sensitive  to  pharmacological  targeting  of  the  MLL1 complex.  a  Dose  response
curves for MI-463 (left) and MI-503 (right) in Cebpa  (red) and Cebpa
 cells  (blue).  b  Colony-formation  assay  of  primary  mouse  Cebpa  and
Cebpa  cells  in  the presence of  MI-463 (4 µM) or  DMSO. Counts  were
normalized to colonies in the DMSO samples for each genotype.) c Left, viability
of primary human leukemia cells after MI-463 treatment (5 days, 4 µM). Data were
normalized to DMSO controls for each patient sample. The dashed line indicates
mean viability of CEBPA-mutant AML samples. Right, Heatmap representation of
half-maximal  effective  concentrations  (EC )  of  MI-463  in  primary  human
leukemia cells. C-term, C-terminal; dm, double-mutated; MLLr, MLL-rearranged;
AML (other): CEBPA-, NPM1- and MLLr-negative
p30/C-mut.
p30/C-mut.
p30/p30 p30/C-
mut. p30/p30
p30/C-mut.
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MI-463 and MI-503 caused a significant decrease in cellular viability and half-
maximal responses in primary human CEBPA-mutated AML samples as well as
in primary human AML cells with MLL-rearrangements and NPM1 mutations,
while it had much weaker effects on the viability of other AML samples negative
for these mutations and on cells from BCR-ABL1-positive chronic myeloid
leukemia (CML) patients (Fig. 4c, Supplemental Figure S4E-F, Supplemental
Table S3).
Taken together, these data reveal that CEBPA-mutated AML is highly sensitive to
pharmacological targeting of the MLL1 complex.
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To investigate the molecular consequences of MLL1 complex perturbation in
CEBPA-mutated AML, we performed RNA sequencing (RNA-seq) upon inhibitor
treatment of Cebpa  cells. Both inhibitors had comparable and strongly
overlapping effects on global gene expression changes (Supplemental
Figure S5A-B). The majority of genes was upregulated in response to either
MI-463 and/or MI-503 (608 upregulated genes vs. 212 downregulated genes;
Supplemental Figure S5C). Gene set enrichment analysis (GSEA) revealed that
inhibitor treatment induced transcriptional changes associated with myeloid
differentiation, whereas self-renewal-associated signatures were depleted
(Fig. 5a, Supplemental Figure S5D). MI-463 and MI-503 treatment caused
upregulation of the myeloid marker gene Lyz2 (Supplemental Figure S5E) and a
time- and dose-dependent increase in surface expression of the myeloid
differentiation markers Mac-1 and Gr-1 (Fig. 5b, Supplemental Figure S5F).
Fig. 5
Loss  of  MLL1  function  restores  terminal  myeloid  differentiation  potential  of
Cebpa  cells. a GSEA showing global upregulation of genes associated with
myeloid  differentiation  in  Cebpa  cells  upon  inhibitor  treatment.  NES,
normalized  enrichment  score.  b  Flow  cytometric  analysis  of  Mac-1  and  Gr-1
surface expression upon MI-463 treatment  at  indicated time points.  c  qRT-PCR
analysis  of  She2  in  Cebpa  cells  upon  inhibitor  treatment  (day  2),
CRISPR/Cas9-mediated  Mll1  mutagenesis  (day  14)  or  shRNA-mediated  Cebpa
knockdown (day 9) relative to control. MI-463: 3.0 µM; MI-503: 2.5 µM
p30/p30
p30/p30
p30/p30
p30/p30
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These results indicate that pharmacological perturbation of the MLL1 complex
can overcome the differentiation block of Cebpa  cells, restoring terminal
myeloid differentiation potential.
Genes with strongly downregulated expression upon Menin-MLL inhibition
showed comparable responses after CRISPR/Cas9-mediated Mll1 targeting and
shRNA-mediated Cebpa knockdown, indicating cooperative gene regulation by
C/EBPα p30 and MLL1 (Fig. 5c, Supplemental Figure S5G). To systematically
identify critical effectors of p30- and MLL1-dependent gene regulation, we
p30/p30
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focused on genes that were upregulated upon C/EBPα p30 overexpression in
myeloid cells [12]. Thirteen genes were induced by p30, downregulated upon
Menin-MLL inhibition and showed robust p30 binding within 10 kb upstream of
their TSS, implying direct, positive transcriptional regulation that depends on
p30 and MLL1 (Supplemental Figure S6A). This list was highly enriched for
factors regulating normal and aberrant hematopoiesis (Supplemental
Figure S6B). In addition to Sox4, a known oncogenic target in CEBPA-mutated
AML [31] (Supplemental Figure S6C-D), Gata2 fulfilled all criteria for a
potential effector of the p30-MLL1 axis. GATA2, is a zinc-finger TF that is
frequently de-regulated or mutated in leukemia [32, 33, 34]. Gata2 expression
was upregulated by p30 and strongly downregulated upon Menin-MLL inhibitor
treatment (Fig. 6a, Supplemental Figure S6E). CRISPR/Cas9-mediated
mutagenesis of Gata2 (Supplemental Figure S6F) caused a rapid decrease of
GFP  sgRNA-expressing cells and induced terminal myeloid differentiation
(Fig. 6b, c). p30 and MLL1 showed extensive co-localization in the Gata2
promoter, suggesting cooperative regulation of Gata2 expression (Fig. 6d, e).
Indeed, MI-463 treatment of Cebpa In the PDF document, this word is
seperated over the line break. Please keep as one word cells resulted in a strong
decrease in MLL1 occupancy at the Gata2 locus (Fig. 6d, f).
Fig. 6
GATA2 is a critical effector of the p30-MLL1 axis. a qRT-PCR analysis of Gata2
in Cebpa  cells treated with MI-463 (3.0 µM) or MI-503 (2.5 µM) for 2 days,
normalized  to  DMSO  treatment.  b  Left,  heatmap  showing  survival  of  GFP
sgGata2-expressing cells (#1–2) over time. Ctrl, negative control; Rpa3, positive
control. Right, scatter plot representing the percentage of GFP  cells (day 11). c
Flow  cytometric  analysis  of  Mac-1  and  Gr-1  surface  expression  after  Gata2
targeting.  d  ChIP-seq  tracks  for  p30  (orange)  and  MLL1  (treated  with  DMSO
(blue) or 3.0 µM MI-463 (petrol)) at the Gata2 promoter in Cebpa  cells. Red
lines indicate positions of ChIP-qPCR products. e ChIP-qPCR analysis of p30 and
MLL1 binding to the Gata2 promoter in Cebpa  cells. f ChIP-qPCR analysis
of MLL1 binding to the Gata2 promoter in Cebpa  cells treated with DMSO
or 3.0 µM MI-463
+
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Together, these results show that p30 and the MLL1 complex cooperatively
regulate Gata2 expression and identify GATA2 as an effector of the p30-
mediated differentiation block and leukemogenesis.
Here we demonstrate that the p30 C/EBPα p30 isoform and the MLL1 complex
co-localize on chromatin, enabling the cooperative regulation of specific target
genes. CEBPA-mutated AML depends on a functional MLL1 complex, as genetic
5'  and  3'  are  labeled  the
wrong way around in Figure
6.  We attached the correct
figure  as
20190114_Figure6-01.tif
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and pharmacological perturbation of its function blocks proliferation and induces
myeloid differentiation in leukemia cells. Thus, this work validates the MLL1
complex as a potential target for therapeutic intervention in CEBPA-mutated
AML.
Our ChIP-seq studies of p30- and MLL1-binding in myeloid progenitors from a
Cebpa  AML mouse model allow for the first time to unambiguously
identify genomic targets of the p30 C/EBPα p30 isoform. This analysis also
identified a high overlap of p30 with MLL1-binding in promoter-proximal
regions. The genomic interaction of p30 with the MLL1 complex was confirmed
by co-immunoprecipitation studies, validating the interaction of p30 with WDR5,
RBBP5, ASH2L, and Menin, which are important factors in regulating assembly,
enzymatic activity, and chromatin-anchoring of the MLL1 complex [19, 22].
CRISPR/Cas9-mediated screening of functional domains of the Mll1 gene
revealed that the enzymatic SET domain appears to be dispensable for
N-terminal CEBPA-mutated AML. Similar findings have been reported in other
systems [35], suggesting significant redundancy among H3K4me3-catalyzing
enzymes in the regulation of normal and aberrant hematopoiesis. C/EBPα p30-
expressing cells were hypersensitive to mutagenesis of the WIN domain, which
is required for the MLL-WDR5 interaction, supporting the important role of
WDR5 in CEBPA-mutated AML in the context of the MLL1 complex [12].
Cebpa  cells were also particularly sensitive to disruption of domains with
known functions in chromatin binding of MLL1, such as the CXXC motif, the
PHD finger, the bromodomain, and the Menin-binding motif (MBM) [22, 36, 37,
38, 39]. Small-molecule-mediated inhibition of the Menin-MLL interaction was
reported to compromise the integrity of the MLL1 complex, resulting in
decreased H3K4me3 levels on MLL1 target genes [25, 26, 27, 29]. In vivo,
pharmacological targeting of the MLL1 complex induced survival benefits in
models of MLL-rearranged and NPM1-mutated AML [28, 29].
CEBPA-mutated AML cells require a functional MLL1 complex, as its
pharmacological perturbation resulted in impaired proliferation, cell cycle arrest
and differentiation. In contrast to other AML subtypes [26, 28], however,
apoptosis appears to be an early event in response to inhibitor treatment in
CEBPA-mutated AML.
In MLL-rearranged and NPM1-mutated AML, MLL1 complex inhibitors block
p30/p30
p30/p30
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leukemia progression via downregulation of the critical target genes HOXA9 and
MEIS1 [26, 27, 29, 40, 41]. However, HOXA9 and MEIS1 do not contribute to
leukemogenesis in CEBPA-mutated AML patient samples and mouse models [24,
42], indicating that MLL1 inhibitor treatment impairs leukemic self-renewal
through different mechanisms in this disease context. In line with this, MLL1 is
able to regulate subsets of transcriptionally active promoters that can strongly
differ in various cell types and diseases [43]. It was proposed that this specificity
is mediated via interactions with cell-type-specific TFs and histone modifications
that shape the epigenetic landscape and regulate MLL1 recruitment to specific
target genes [43]. Thus, it is possible that p30 and MLL1 co-regulate the
expression of specific gene sets that are not shared with other AML subtypes.
To identify potential effector genes of the p30-MLL1 axis that are involved in
aberrant self-renewal of Cebpa  cells, we focused on genes that are
upregulated by p30, downregulated upon Menin-MLL inhibition and exhibit
robust p30 chromatin binding in their promoter regions. This filtering strategy
identified Sox4, a known oncogenic target of CEBPA-mutated AML [31]. Other
genes with known roles in normal and aberrant hematopoiesis or leukemogenesis
were also identified, including Fam20a, Fubp1, and the TFs Erg and Gata2 [34,
44, 45, 46, 47, 48, 49].
Balanced GATA2 expression levels are critical for normal blood cell
differentiation and development [50, 51]. GATA2 is often found mutated and/or
de-regulated in various malignancies [52, 53, 54, 55, 56]. Whereas gain-of-
function mutations in GATA2 were detected in CML [54], AML patients often
display increased levels of GATA2 expression, which correlates with poor
prognosis [33, 55]. Interestingly, heterozygous deletion [57], but also low-level
overexpression of GATA2 [32] was linked to accelerated leukemogenesis and
increased progenitor self-renewal, highlighting the detrimental consequences of
any de-regulation of GATA2 expression.
We found that Cebpa  cells are highly dependent on GATA2 function, as
CRISPR/Cas9-mediated Gata2 mutagenesis led to a strong reduction of
proliferative capacity and a substantial induction of myeloid differentiation.
C/EBPα In the PDF document, this word is seperated over the line break. Please keep
as one word  p30 and MLL1 co-localized on the Gata2 promoter, implying
cooperative regulation of Gata2 expression. Treatment of Cebpa  cells with
p30/p30
p30/p30
p30/p30
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Menin-MLL inhibitors resulted in a decrease in MLL1 occupancy at the Gata2
promoter, indicating a direct role of MLL1 in the regulation of Gata2 expression
in CEBPA-mutated AML.
In summary, our results identify a critical link between the C/EBPα p30 variant
and the MLL1 complex and show that perturbation of the MLL1 complex could
represent a novel therapeutic strategy for patients with CEBPA-mutated AML.
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